Patent ID: 7691897
Filing Date: 2010-04-06
Classification: A61K,A61P

Abstract:
1. A method for the depletion of a protein population from the plasma of a subject in need of such treatment, which comprises: (a) administering to the subject a therapeutically effective amount of a nonproteinaceous agent, wherein the agent is a D-proline of the formula: wherein R is the group R X is —(CH Y is —S—S—; —(CH. X′ is —(CH —CH(OH)CH R n is 0-3, or a pharmaceutically acceptable salt or mono- or diester thereof; which agent comprises a plurality of ligands covalently co-linked to permit complexation with a plurality of the proteins in the presence thereof, wherein at least two of the ligands are the same or different and are capable of being bound by ligand binding sites present on the proteins; (b) binding of at least two of the ligands by the ligand binding sites of the proteins in the plasma; (c) forming thereby a complex between the agent and a plurality of the proteins, wherein the complex is abnormal to the subject; and (d) causing the complex to be identified by the physiological mechanisms of the subject and cleared from the plasma; and (e) monitoring the clearance of the disease-associated protein population from the subject's plasma; wherein the ligand binding site is from serum amyloid P component (SAP).